Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > Dear Friend;Dr. George Adams 👀Visionary with Ventripoint🚀
View:
Post by jopatclo on Oct 24, 2024 9:06am

Dear Friend;Dr. George Adams 👀Visionary with Ventripoint🚀

 Dear Friend;
 
Attached is today's news release and here is some background on its significant for the Company.  
 
1. A lot can happen in two weeks!  We announced the Company passed the EU-MDR audit for its quality systems on Oct 8, which was a prerequisite to the EU review of our submission for clearance for the VMS+4.0 product, which we announced submitting on Oct 11th.  Here its October 24 and we now have CE Mark for VMS+4.0.
2. You may remember we predicted the CE Mark would come in November so it was a surprise even to us it came so quickly and is a credit to our team for submitting such a stellar package for review.
3. This is very good news as we have several dozen hospitals in Europe who have asked to be kept informed about when the VMS+4.0 would be available.  This is due to the world-first nature of having a fully-automated whole-heart analysis capability.
4. In Europe, it is the cardiologist who do the exam and collect the images as well as do the analysis and then decide upon treatment (In North America technicians - sonographers - collect the images and do the analysis which is reviewed by the cardiologist).  In Europe the cardiologist often goes with the patient for the MRI exam if the echo exam is inconclusive, so they are acutely aware of the difficulties of doing MRI and are looking for alternatives. 
5. The VMS+4.0 is faster, more consistent analysis results as well as number of new measurements of heart function, which need to be validated as useful, but our medical advisors are excited about the possibilities and are looking at a  number of new adult patients groups who would benefit from this increased information for screening, diagnosis and monitoring.
6. All this is good but it is really the major upgrade in the integration of the VMS+ into the normal workflow within an echocardiography service that is the game changer.  I have spoken to you before about the tsunami of patients just starting to show up with heart problems due the aging population (left heart problems) and the COVID pandemic (right heart problems).  The predictions (from Harvard University experts) of 10-15% of people infected (and I would argue that was everyone in the world) will have long-term effects is coming true.
7. So a faster, reliable, accurate way to assess the whole heart (left and right) is only going to become essential if all these new patients are going to be properly diagnosed and treated given the shortage of echocardiography clinicians 
8. I could go one for days about the nuances of the VMS+4.0 approach to cardiac care, but enough for now.
9. The Company now will begin to circle back to all those clinicians in Europe to make them aware of the VMS+4.0 which will be sold as a premium product.  the VMS+3.0 is being used by our users now and some have been upgraded to VMS+3.2 which will be the base unit going forward.  We anticipate VS+4.0 will be the model most desired and the added cost will not stop hospitals from acquiring this more efficient and powerful system that will address their greatest need which is workflow efficiency.
 
Thank for you interest and support as we continue too improve Cardiac diagnostics for everyone everywhere, and especially for children born with great defects.
 
Regards,
 
Dr. George Adams ICD.D
Comment by riverrrow on Oct 24, 2024 1:39pm
"This is due to the world-first nature of having a fully-automated whole-heart analysis capability".   I like to think this is what clinicians have been waiting for and now that it's here sales should start happening.  GLTA.
Comment by jopatclo on Oct 31, 2024 9:33am
 Something could happen anytime real fast! FDA V4.0 and Sales at any time now Now That V4.0 Europe V4.0 ok & Canada (The BEST automation and analysis of the PLANET GEN3EHO https://ascendcv.com/ The Ollie Hinkle Foundation posted videos of their Take Heart 2024 conference on YouTube.https://www.youtube.com/watch?app=desktop&v=Ucu6uGRMtEs) Reminder of July 5, 2023 Ventripoint ...more  
Comment by jopatclo on Oct 31, 2024 11:49am
Interesting see post on Linkedin  Celebrating 10 years of the Philips Foundation : a decade of making waves in healthcare. & I think Dr. Adams is a visionary with Ventripoint for the health of children and now also for all. Vasana InsisiengmayVasana Insisiengmay • 3rd+ • 3rd+Talent Acquisition Senior Manager, North America Region | Philips | People AdvocateTalent ...more  
Comment by jopatclo on Oct 31, 2024 2:06pm
Dr. Adams is a visionary with Ventripoint I think they know more about the Ventripoint tech than the whiners on this board. See very positive FDA V4.0 and Sales at any time now Insiders know! and now *Dr.Brian Soriano MD, FASE | Cardiologist, Associate Professor, Cardiology, and Adjunct Associate Professor, Radiology, Seattle Children’s Hospital              ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities